EZZ Life Science Holdings Ltd. (EZZ) AI Stock Analysis

• Market Cap: AU$59.51M
• Dividend Yield: 2.81%
• Average Volume (3M): 49.70K
• Price to Earnings (P/E): 25.1
• Beta (1Y): 0.18
• Revenue Growth: 0.65%
• EPS Growth: -9.90%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 47,043,200
• 10 Day Avg. Volume: 67,551
• 30 Day Avg. Volume: 49,696
• PEG Ratio: -2.57
• Price to Book (P/B): 3.85
• Price to Sales (P/S): 1.62
• P/FCF Ratio: 26.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: AU$1.50 ▲(3.45% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily supported by strong profitability and a low-leverage balance sheet, but it is materially weighed down by bearish technicals (price below all major moving averages and negative MACD) and recent business/cash flow softness (revenue decline and weaker operating cash conversion). Valuation is neutral-to-slightly supportive due to the dividend yield despite a higher P/E.

Positive Factors

High margins

Sustained gross margins above 70% and a ~10% net margin indicate durable product-level pricing power and favorable unit economics typical of branded nutraceuticals. High margins provide a buffer vs. cost inflation, support R&D/marketing reinvestment and long-term cash generation.

Low leverage and strong ROE

A very low debt-to-equity profile and robust return on equity give the company financial flexibility to fund growth, withstand demand shocks, and invest in distribution or product development without material refinancing risk, strengthening long-term stability.

Diversified channels and cross-border reach

Having both direct-to-consumer online channels and wholesale distribution plus cross-border e-commerce into Asian markets reduces concentration risk, supports scalable growth, and positions the company to capture secular demand for health products in higher-growth regional markets.

Negative Factors

Revenue decline and volatility

A ~10.9% revenue decline in the latest year and noted volatility in revenue growth suggest weakening end-market demand or execution issues. Persistent top-line weakness can erode economies of scale, pressure margins and limit the firm's ability to invest for durable growth.

Weak cash conversion

Operating cash flow less than reported net income and a recent decline in free cash flow growth indicate weaker cash conversion. This reduces internal funding for capex, marketing or dividends and increases dependence on external financing during downturns, a durable financial constraint.

Negative EPS growth

Negative EPS growth near -10% signals earnings pressure beyond transient items. Continued EPS contraction undermines retained earnings and limits the company's capacity to self-fund product development or expand distribution, posing sustained risk to financial resilience.

EZZ Life Science Holdings Ltd. Business Overview & Revenue Model

Company Description

EZZ Life Science Holdings Limited provides skin care and consumer health products in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned products. It is involved in the wholesale distribution of EAORON branded skin care products to pharmacies, supermarkets, and specialist retailers, as well as grocery retailers. The company also designs, develops, produces, distributes, and sells consumer health products, including vitamins and dietary supplements, sports nutrition, weight management and wellbeing, herbal/traditional, and paediatric products under the EZZ brand through its e-commerce platforms and stores, such as Tmall Global. EZZ Life Science Holdings Limited was incorporated in 2015 and is based in Silverwater, Australia.

How the Company Makes Money

EZZ generates revenue through the sale of its dietary supplements and health products, which are marketed both online and through retail partnerships. The company employs a multi-channel distribution strategy, leveraging e-commerce platforms and traditional retail outlets to reach a broad audience. Key revenue streams include direct-to-consumer sales via their website and partnerships with health and wellness retailers. Additionally, EZZ may engage in strategic collaborations with other companies in the health sector to expand its product offerings and market reach, contributing to its overall earnings.

EZZ Life Science Holdings Ltd. Financial Statement Overview

Summary

Overall fundamentals are solid, supported by strong profitability (gross margin consistently above 70% and net margin around 10%) and a strong balance sheet with very low leverage and robust ROE. The score is held back by volatility and a recent revenue decline (down 10.88%) plus weaker cash conversion (operating cash flow to net income below 1) and a decline in free cash flow growth.

Income Statement

EZZ Life Science Holdings Ltd. shows strong profitability with a consistent gross profit margin above 70% and a net profit margin around 10%. However, the revenue growth rate has been volatile, with a significant decline of 10.88% in the latest year. Despite this, EBIT and EBITDA margins remain healthy, indicating efficient operations.

Balance Sheet

The company maintains a very low debt-to-equity ratio, indicating minimal leverage risk. Return on equity is robust, reflecting effective use of equity to generate profits. The equity ratio is solid, suggesting a strong capital structure with a high proportion of assets financed by equity.

Cash Flow

Cash flow metrics indicate some challenges, with a significant decline in free cash flow growth recently. The operating cash flow to net income ratio is below 1, suggesting potential issues in converting income into cash. However, the free cash flow to net income ratio is close to 1, showing that free cash flow generation is relatively aligned with net income.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	61.40M	66.87M	66.44M	37.14M	15.02M	22.29M
Gross Profit	41.95M	49.72M	50.95M	27.20M	7.51M	12.46M
EBITDA	5.42M	11.10M	10.38M	5.09M	1.90M	2.87M
Net Income	2.89M	6.73M	6.96M	3.63M	1.31M	2.03M
Balance Sheet
Total Assets	32.60M	33.96M	25.55M	17.64M	14.27M	12.04M
Cash, Cash Equivalents and Short-Term Investments	13.47M	20.85M	19.02M	13.83M	10.46M	8.85M
Total Debt	123.86K	304.49K	123.86K	478.59K	104.57K	79.01K
Total Liabilities	4.80M	5.87M	4.23M	3.06M	2.88M	1.93M
Stockholders Equity	27.81M	28.09M	21.32M	14.58M	11.39M	10.11M
Cash Flow
Free Cash Flow	-2.69M	4.09M	5.73M	3.91M	1.89M	237.42K
Operating Cash Flow	-2.62M	4.35M	6.14M	4.01M	1.90M	253.53K
Investing Cash Flow	-862.95K	-546.93K	-441.17K	-101.78K	-13.18K	-16.12K
Financing Cash Flow	-2.20M	-2.17M	-582.45K	-761.72K	-277.36K	5.44M

EZZ Life Science Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Negative. The current price of 1.45 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.67, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 28.86 is Positive, neither overbought nor oversold. The STOCH value of 16.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EZZ.

EZZ Life Science Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	60 Neutral	AU$59.51M	25.12	27.24%	2.81%	0.65%	-9.90%
RCE	52 Neutral	AU$150.38M	-4.57	―	―	―	0.66%
ALA	52 Neutral	AU$95.37M	-11.29	-47.98%	―	700.00%	26.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATX	43 Neutral	AU$61.57M	-5.97	-27.39%	―	―	26.64%
ATH	41 Neutral	AU$87.00M	-6.67	-42.68%	―	―	63.46%
IMU	40 Underperform	AU$69.13M	-0.96	-83.09%	―	―	55.94%

EZZ Life Science Holdings Ltd. Corporate Events

EZZ Life Science Swings to Half-Year Loss as Revenue Falls but Balance Sheet Stays Solid

EZZ Life Science Holdings Limited reported an 18.07% decline in revenue to $24.8 million for the half-year to 31 December 2025 and swung from a prior profit to a net loss after tax of $641,298. Despite this, the group generated normalised EBITDA of $2.0 million, down from $5.5 million a year earlier, while net tangible assets per share rose to 59.03 cents, supported by higher net tangible assets and expanded share capital through employee incentive share issues and performance rights exercises.

The company’s net assets eased slightly to $27.8 million over the half-year, reflecting the reported loss, yet it maintained capital returns with a fully franked final dividend of 2.0 cents per share paid in December 2025. The figures highlight pressure on profitability and margins even as the balance sheet remains solid, signaling a period of investment and cost absorption that may affect near-term returns for shareholders but underpins ongoing employee alignment and growth initiatives.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Balances China Headwinds With Expansion, Governance Reset and Strong Cash Position

EZZ Life Science Holdings reported a challenging December 2025 quarter marked by softer market conditions and heightened competition in China, which drove a 26% year-on-year decline in customer receipts despite a modest improvement on the prior quarter. The company recorded an operating cash outflow of $2.2 million, largely due to significant tax payments and elevated marketing spend ahead of its Australian Open 2026 sponsorship, but underlying cash performance improved versus the prior quarter and EZZ ended the period with $13.5 million in cash and no debt, while also paying a final FY25 dividend. Operationally, EZZ continued to expand its domestic pharmacy footprint with 10 additional Australian stores, bolster brand visibility through major international expos and Australian Open-related events in Shanghai, and maintained leading rankings on Chinese e-commerce platforms during the Double 11 festival. Strategically, the company reshaped its leadership structure by appointing former chair Glenn Cross as Chief Strategy Officer to spearhead its U.S. expansion and strengthening its board with new executive and non-executive directors, including a new non-executive chair to enhance governance and separate board and management roles, while choosing not to proceed with a proposed acquisition to preserve balance sheet flexibility and maintain a prudent capital position.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Appoints Gary Liu to Board with No Initial Shareholding

EZZ Life Science Holdings Limited has announced the appointment of Gary Liu as a director, effective 22 January 2026, and lodged an Initial Director’s Interest Notice with the ASX. The filing confirms that Liu currently holds no relevant interests in the company’s securities, either directly or indirectly, and has no disclosed interests in contracts, indicating a starting position free of shareholdings or related-party financial arrangements as he joins the board.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Names Gary Liu as Non-Executive Chair to Support Global Growth

EZZ Life Science Holdings has appointed Gary Liu as Non-Executive Chair of the board, effective immediately, bringing significant international experience in listed company leadership, capital markets, strategy and M&A, with a strong focus on Asia-Pacific markets. The move is intended to strengthen the company’s governance framework and board capability as it pursues its growth strategy and expands internationally, and will allow CEO Mark Qin, who had been Interim Chair, to concentrate solely on executive operations, reinforcing a clearer separation between board oversight and management responsibilities.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science bolsters board with two new director appointments

EZZ Life Science Holdings Limited has strengthened its board by appointing Christine Chen as Executive Director and Janice Hsu as Non-Executive Director, effective immediately. Chen, a long-standing executive with the company and a qualified accounting and tax professional, formalises her pivotal role in finance, compliance and governance, providing continuity and technical depth at the executive level. Hsu brings experience in administration, stakeholder engagement and community services, adding a people-focused and governance-oriented perspective that is expected to support board oversight as EZZ scales its operations and executes its growth strategy.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Reports Lapse of Conditional Securities

EZZ Life Science Holdings has notified the market of the cessation of several classes of securities, with 10,000 performance rights and a total of 130,000 ordinary fully paid shares lapsing after the conditions attached to those securities were not met or became incapable of being satisfied between October 2025 and early January 2026. The lapses reduce potential future dilution from these conditional equity instruments and slightly adjust the company’s issued capital profile, but do not reflect any change in its core operations, instead signalling that certain performance or vesting hurdles tied to those securities were not achieved.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Director Increases Shareholding

EZZ Life Science Holdings Ltd. announced a change in the director’s interest, with Ivan Oshry increasing his direct shareholding by converting 5,000 performance rights into ordinary shares. This change reflects a strategic move in the company’s governance, potentially impacting shareholder confidence and market perception.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Announces Director Departure

EZZ Life Science Holdings Limited announced the cessation of Glenn Cross as a director effective 28 November 2025. This change in the board may influence the company’s strategic direction and could have implications for its stakeholders, as Cross held significant interests in the company, including 45,000 fully paid ordinary shares and 10,000 performance rights.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.